GSK, Roche, and Alumis Shift
Kilder
- Endpoints: GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
- BioSpace: GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality - BioSpace
- Fierce Biotech: GSK plans phase 3 after mRNA flu vaccine beats standard shots - Fierce Biotech
- Endpoints: Roche taps Simcere for trispecific T cell engager pact with $75M upfront
- Pharmaphorum: Roche taps Simcere for autoimmune trispecific for $1.53bn - pharmaphorum
- Fierce Biotech: Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody - Fierce Biotech
- Endpoints: Lilly’s 2026 dealmaking spreads the wealth among biotech venture investors
- Endpoints: Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
- BioPharma Dive: Alumis’ TYK2 drug fails in key lupus study - BioPharma Dive
- STAT: STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.